ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV) is among the top losers of the stock market today, sinking -1.4% or (0 points) to $0.12 from its previous close of $0.12. Does this decline mean it the best stock to buy right now? The shares seem to have an active trading volume day with a reported 1454359 contracts so far this session. CTRV shares had a relatively better volume day versus average trading capacity of 3.02 million shares, but with a 26.89 million float and a -12.16% run over a week, it’s definitely worth keeping an eye on. The one year price forecast for CTRV stock indicates that the average analyst price target is $2 per share. This means the stock has a potential increase of 1566.67% from where the CTRV share price has been trading recently which is between $0.11 and $0.13.
The shorts are climbing into ContraVir Pharmaceuticals, Inc. (CTRV) stock. The latest set of short interest data was released on 30 April 2019, and the numbers show a rise in short interest in CTRV shares. While short interest still represents only 1.49% of CTRV’s float, the number of shares shorted have risen by 36653. The number of shares shorted advanced to 438236 shares, up from 401583 shares during the preceding fortnight. With average daily trading volumes at 6011300 shares, days to cover decreased to about 1 days. The most recent news story about the stock that appeared in Yahoo Finance‘s news section was titled “ContraVir Pharmaceuticals Receives Positive Nasdaq Listing Decision” and dated May 06, 2019.
During the recent trading session for ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), the company witnessed their stock drop by $-0.01 over a week and tumble down $-0.11 from the price 20 days ago. When compared to their established 52-week high of $2.6, the high they recorded in their recent session happens to be lower. Their established 52-week high was attained by the company on 05/29/18. The recent low of $0.1 stood for a -95.4% since 04/25/19, a data which is good for most investors who are looking to take advantage of the stock’s recent rise. A beta of 1.21 is also allocated to the stock. Since the beta is greater than one, it implies that the stock is more volatile than the market, a data that traders are keeping close attention to.
Looking at the current readings for ContraVir Pharmaceuticals, Inc., the two-week RSI stands at 33.95. This figure suggests that CTRV stock, for now, is neutral, meaning that the shares are stable in terms of price movement. The stochastic readings, on the other hand, based on the current CTRV readings is similarly very revealing as it has a stochastic reading of 18.34% at this stage. This figure means that CTRV share price today is being overbought.
Technical chart claims that ContraVir Pharmaceuticals, Inc. (CTRV) would settle between $0.13/share to $0.14/share level. However, if the stock price goes below the $0.11 mark, then the market for ContraVir Pharmaceuticals, Inc. becomes much weaker. If that happens, the stock price might even plunge as low as $0.1 for its downside target. The stock is currently in the red zone of MACD, with the indicator reading -0.01. Traders are always alerted for the move of a stock above or below the zero line due to the fact that the reading is an indicator of the position of the short-term average relative to the long-term average. If the MACD is above the zero line, then the short-term average relative is above that of the long-term average, thus implying an upward momentum. Vice versa is the case if the MACD is below the zero line.
Analysts at Maxim Group raised their recommendation on shares of CTRV from Hold to Buy in their opinion released on July 10. Maxim Group analysts have lowered their rating of ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV) stock from Buy to Hold in a separate flash note issued to investors on February 13. Analysts at Maxim Group, made their first call for the equity with a Buy recommendation, according to a research note that dated back to May 06.
CTRV equity has an average rating of 3, with the figure leaning towards a bullish end. 1 analysts who tracked the company were contacted by Reuters. Amongst them, 1 rated the stock as a hold while the remaining 0 were split even though not equally. Some analysts rate the stock as a buy or a strong buy while no rated it as a sell. 0 analysts rated ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV) as a buy or a strong buy while not a single analyst advised that investors should desist from purchasing the stock or sell them if they already own the company’s stock.